Midomafetamine
- Generic Name
- Midomafetamine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H15NO2
- CAS Number
- 42542-10-9
- Unique Ingredient Identifier
- KE1SEN21RM
- Background
An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.
- Indication
Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.
- Associated Conditions
- -
- Associated Therapies
- -
Startups Are Biohacking Psychedelic Drugs to Make Sure You Never Have a Bad Trip Again
Pharmaceutical companies are developing safer psychedelic drugs for psychotherapy, with MindMed creating R-MDMA with fewer side effects. Other companies aim to synthesize DMT for longer-lasting depression relief. Despite MDMA's Schedule I status, studies suggest it treats PTSD and depression. Countries like Portugal and Australia have decriminalized or legalized MDMA for personal use or therapy. Mindstate uses AI to understand brain effects and received FDA approval for human trials of MSD-001, targeting specific serotonin receptors.
Hallucinogenic mushrooms are better at treating depression than conventional medicine
A European study suggests 'magic' mushrooms, specifically psilocybin, are more effective at treating depression than conventional SSRIs, with rapid and lasting benefits. Psilocybin, granted 'breakthrough therapy' status by the FDA, may rewire the brain, offering relief to those with treatment-resistant depression. Challenges include stigma, cost, and the need for supervised administration.
Pα+ Psychedelic Bulletin #176: Drug Developers Discuss Trial Design; Massachusetts Vote
At TD Cowen’s September 26th panel, 'Advancement in Psychedelic Therapies for Neuropsychiatry,' execs from atai Life Sciences, Cybin, and GH Research discussed Lykos’ new drug application, psychedelic trial design, and the broader field. atai CEO Srini Rao emphasized the FDA’s consistent standards for psychedelics, referencing Janssen’s Spravato approval. Cybin’s CSO, Amir Inamdar, criticized Lykos’ psychotherapeutic approach as unethical, and highlighted the impracticality of psychotherapy during active dosing sessions.
Microdosing Psilocybin: Popular Drug Has Implications for the Workplace
The article discusses psilocybin's therapeutic potential, state laws on its use, and employer responses to employee microdosing. It highlights federal illegality under the Controlled Substances Act, contrasting with state-level decriminalization efforts. Employers are advised to clarify drug use policies, offer employee assistance programs, and ensure safety in safety-sensitive roles.
Psychedelic drugs have great therapeutic promise. But Question 4 goes too far.
Question 4 proposes legalizing home growing and unregulated consumption of five psychedelic drugs, despite health risks. The board recommends voting no, suggesting a committee of experts to create a regulated framework. FDA approval is crucial for ensuring drug safety and efficacy. The initiative includes therapeutic centers with trained facilitators, but allowing home grows contradicts rigorous oversight. If passed, strict regulations are needed to protect public safety.
Canadian Biotech Company to Supply MDMA for Pending HMS Clinical Trial
PharmAla Biotech signed a contract to supply MDMA to Harvard Medical School for a clinical trial on borderline personality disorder. The trial, pending grant funding, aims to study MDMA's mechanistic effects. PharmAla supports researchers with a customer-centric approach, facilitating the complex regulatory process required for MDMA trials.
Delhi police launch hunt for drug peddlers
Synthetic drugs like MDMA are becoming prevalent in Delhi-NCR, with Dwarka and Greater Noida as hotspots for narcotics consumption and smuggling. Delhi Police recently busted an inter-state supply network, seizing 1,200 grams of hashish and 90 grams of heroin. The accused, Ajay Lal, a 63-year-old man, was involved in drug trade after serving time in Nepal for cheating.
How One Biotech Is Using FDA 505(b)(2) To Get Drugs To Patients Quicker And Cheaper
Terran Biosciences, led by CEO Sam Clark, is leveraging the FDA's 505(b)(2) pathway to expedite the development of TerXT, a new treatment for schizophrenia. By referencing data from Bristol Myers Squibb's Cobenfy, Terran aims to create a once-daily oral dose and a long-acting injectable version of TerXT, addressing Cobenfy's limitations. This approach, which includes the use of prodrugs, aims to provide more affordable and accessible treatment options for patients.
PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA
PharmAla Biotech contracted to supply MDMA for a clinical trial at the University of Texas, San Antonio, aiming to develop a new dosage form. The company also announced the publication of a patent related to its APA-01 novel molecular entity, part of its IP strategy.
Wisconsin is on the front lines of psychedelic research that could reach millions
Psilocybin, found in magic mushrooms, shows promise in treating clinical depression when combined with therapy, according to Wisconsin researchers. Estimates suggest 6 million U.S. patients could benefit if approved, though challenges include cost and regulatory hurdles.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath